Evidence map›Paper›PMID 36643629›Full record

ArticlePeerJ2023

CMTM6 is highly expressed in lung adenocarcinoma and can be used as a biomarker of a poor diagnosis.

Daqi Jia, Li Xiong, Honggang Xue, Jidong Li

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PeerJ, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Daqi Jia *Department of Pathology, Kunming Medical University, Kunming, Yunan, China.
Li Xiong *Department of Anesthesiology, The Third People's Hospital of Yibin, Yibin, Sichaun, China.
Honggang XueDepartment of Respiratory and Critical Care Medicine, General Hospital of Fuxin Mining Industry Group of Liaoning Health Industry Group, Fuxin, Liaoning, China.
Jidong LiDepartment of Anesthesiology, The Third People's Hospital of Yibin, Yibin, Sichaun, China.
Second People’s Hospital of Yibin · CNKunming Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: CMTM6 which is chemokine-like factor (CKLF)-like Marvel transmembrane domain containing family member 6 is involved in the occurrence and progression of various tumors. However, the role of CMTM6 is still unclear in lung adenocarcinoma (LUAD). Methods: Immunohistochemical, Western blotting and RT‒PCR methods were used to detect the expression of CMTM6 in LUAD. Cox regression and the Kaplan‒Meier method were performed to assess overall survival. Immunogenic features were evaluated according to immune cell infiltrations, immune checkpoints. The sensitivity to chemotherapy agents was estimated using the pRRophetic package. Results: In LUAD, the expression of CMTM6 was obviously upregulated and was significantly associated with T stage ( Conclusion: This study confirmed that CMTM6 is highly expressed in LUAD and is a new independent poor prognostic factor. In addition, the high expression of CMTM6 is closely related to the tumor microenvironment and immunotherapy, providing new ideas for the treatment of posterior LUAD.

Indexed as

Adenocarcinoma of LungLung NeoplasmsMARVEL Domain-Containing ProteinsBiomarkersBlotting, WesternHumansMyelin ProteinsTumor MicroenvironmentBiomarkersCMTM6 protein, humanMARVEL Domain-Containing ProteinsMyelin ProteinsCMTM6Immune cellImmunotherapyLung cancerPrognosisTumor microenvironment

Identifiers

PMID36643629
PMCPMC9838204
OpenAlexW4315486462

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.